BROWN MICHAEL S 4
4 · REGENERON PHARMACEUTICALS, INC. · Filed Dec 29, 2023
Insider Transaction Report
Form 4
BROWN MICHAEL S
Director
Transactions
- Exercise/Conversion
Common Stock
2023-12-27$482.68/sh+2,049$989,011→ 3,296 total - Sale
Common Stock
2023-12-27$898.00/sh−2,049$1,840,002→ 1,247 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2023-12-27−2,049→ 0 totalExercise: $482.68Exp: 2031-01-04→ Common Stock (2,049 underlying)
Holdings
- 6,162(indirect: By Trust)
Common Stock
- 5,000(indirect: by SLAT)
Common Stock
Footnotes (3)
- [F1]Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 24, 2023.
- [F2]These shares are held in a trust for the benefit of the reporting person's immediate family members. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- [F3]On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant.